Overview

The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The aim of this Phase 3 study is to evaluate the efficacy of isoquercetin as compared to the placebo in prevention of thromboembolic events in patients with metastatic pancreatic cancer.
Phase:
PHASE3
Details
Lead Sponsor:
Quercis Pharma AG
Treatments:
isoquercitrin